{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:07:11Z","timestamp":1790399231793,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000654","name":"Marie Curie","doi-asserted-by":"publisher","award":["PCIG14-GA-2013-631149"],"award-info":[{"award-number":["PCIG14-GA-2013-631149"]}],"id":[{"id":"10.13039\/501100000654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-17-179-04"],"award-info":[{"award-number":["IRG-17-179-04"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["GTDR17500160"],"award-info":[{"award-number":["GTDR17500160"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA267101"],"award-info":[{"award-number":["R01-CA267101"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["2P20GM109091-06"],"award-info":[{"award-number":["2P20GM109091-06"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10549-022-06569-5","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T22:05:09Z","timestamp":1648245909000},"page":"331-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Targeting HIF1-alpha\/miR-326\/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer"],"prefix":"10.1007","volume":"193","author":[{"given":"Ridho","family":"Assidicky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unal Metin","family":"Tokat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Oguzhan","family":"Tarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozge","family":"Saatci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin Gulizar","family":"Ersan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Ogul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Riazalhosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8033-7089","authenticated-orcid":false,"given":"Ozgur","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"6569_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"6569_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pharmthera.2019.02.006","volume":"199","author":"SY Hwang","year":"2019","unstructured":"Hwang SY, Park S, Kwon Y (2019) Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther 199:30\u201357. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.02.006","journal-title":"Pharmacol Ther"},{"issue":"6","key":"6569_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mds187","volume":"23","author":"P Boyle","year":"2012","unstructured":"Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(6):7\u201312. https:\/\/doi.org\/10.1093\/annonc\/mds187","journal-title":"Ann Oncol"},{"key":"6569_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13:674\u2013690. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"key":"6569_CR5","doi-asserted-by":"publisher","first-page":"26406","DOI":"10.18632\/oncotarget.25413","volume":"9","author":"A Santonja","year":"2018","unstructured":"Santonja A, Sanchez-Munoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacon JI et al (2018) Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget 9:26406\u201326416. https:\/\/doi.org\/10.18632\/oncotarget.25413","journal-title":"Oncotarget"},{"key":"6569_CR6","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329\u20132334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1109","journal-title":"Clin Cancer Res"},{"key":"6569_CR7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1186\/s12885-018-4925-1","volume":"18","author":"P Gass","year":"2018","unstructured":"Gass P, Lux MP, Rauh C, Hein A, Bani MR, Fiessler C et al (2018) Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer 18:1051. https:\/\/doi.org\/10.1186\/s12885-018-4925-1","journal-title":"BMC Cancer"},{"key":"6569_CR8","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.3747\/co.25.3954","volume":"25","author":"JM Lebert","year":"2018","unstructured":"Lebert JM, Lester R, Powell E, Seal M, McCarthy J (2018) Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 25:S142\u2013S150. https:\/\/doi.org\/10.3747\/co.25.3954","journal-title":"Curr Oncol"},{"key":"6569_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275\u20131281. https:\/\/doi.org\/10.1200\/JCO.2007.14.4147","journal-title":"J Clin Oncol"},{"key":"6569_CR10","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108\u20132121. https:\/\/doi.org\/10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"key":"6569_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan TE, Tolaney SM (2020) Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw 18:479\u2013489. https:\/\/doi.org\/10.6004\/jnccn.2020.7554","journal-title":"J Natl Compr Canc Netw"},{"key":"6569_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR et al (2019) Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 380:741\u2013751. https:\/\/doi.org\/10.1056\/NEJMoa1814213","journal-title":"N Engl J Med"},{"key":"6569_CR13","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.devcel.2010.05.012","volume":"18","author":"M Egeblad","year":"2010","unstructured":"Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18:884\u2013901. https:\/\/doi.org\/10.1016\/j.devcel.2010.05.012","journal-title":"Dev Cell"},{"key":"6569_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","volume":"6","author":"E Henke","year":"2019","unstructured":"Henke E, Nandigama R, Ergun S (2019) Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 6:160. https:\/\/doi.org\/10.3389\/fmolb.2019.00160","journal-title":"Front Mol Biosci"},{"key":"6569_CR15","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41467-020-16199-4","volume":"11","author":"O Saatci","year":"2020","unstructured":"Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE et al (2020) Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat Commun 11:2416. https:\/\/doi.org\/10.1038\/s41467-020-16199-4","journal-title":"Nat Commun"},{"key":"6569_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41419-019-1593-2","volume":"10","author":"S Berrazouane","year":"2019","unstructured":"Berrazouane S, Boisvert M, Salti S, Mourad W, Al-Daccak R, Barabe F et al (2019) Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia. Cell Death Dis 10:357. https:\/\/doi.org\/10.1038\/s41419-019-1593-2","journal-title":"Cell Death Dis"},{"key":"6569_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","volume":"35","author":"J Cooper","year":"2019","unstructured":"Cooper J, Giancotti FG (2019) Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell 35:347\u2013367. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.007","journal-title":"Cancer Cell"},{"key":"6569_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12885-017-3953-6","volume":"18","author":"CJ Lovitt","year":"2018","unstructured":"Lovitt CJ, Shelper TB, Avery VM (2018) Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins. BMC Cancer 18:41. https:\/\/doi.org\/10.1186\/s12885-017-3953-6","journal-title":"BMC Cancer"},{"key":"6569_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12885-021-07996-1","volume":"21","author":"H Zhu","year":"2021","unstructured":"Zhu H, Wang G, Zhu H, Xu A (2021) ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors. BMC Cancer 21:269. https:\/\/doi.org\/10.1186\/s12885-021-07996-1","journal-title":"BMC Cancer"},{"key":"6569_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24228","author":"C Zhou","year":"2022","unstructured":"Zhou C, Shen Y, Wei Z, Shen Z, Tang M, Shen Y et al (2022) ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma. J Clin Lab Anal. https:\/\/doi.org\/10.1002\/jcla.24228","journal-title":"J Clin Lab Anal"},{"key":"6569_CR21","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1158\/0008-5472.CAN-11-0277","volume":"71","author":"LA Gilbert","year":"2011","unstructured":"Gilbert LA, Hemann MT (2011) Chemotherapeutic resistance: surviving stressful situations. Cancer Res 71:5062\u20135066. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0277","journal-title":"Cancer Res"},{"key":"6569_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071586","author":"DA Senthebane","year":"2017","unstructured":"Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Mazeedi M et al (2017) The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18071586","journal-title":"Int J Mol Sci"},{"key":"6569_CR23","doi-asserted-by":"publisher","first-page":"17296","DOI":"10.1073\/pnas.0508647102","volume":"102","author":"D Hwang","year":"2005","unstructured":"Hwang D, Rust AG, Ramsey S, Smith JJ, Leslie DM, Weston AD et al (2005) A data integration methodology for systems biology. Proc Natl Acad Sci U S A 102:17296\u201317301. https:\/\/doi.org\/10.1073\/pnas.0508647102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6569_CR24","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1158\/0008-5472.CAN-16-1580","volume":"76","author":"TC Archer","year":"2016","unstructured":"Archer TC, Fertig EJ, Gosline SJ, Hafner M, Hughes SK, Joughin BA et al (2016) Systems approaches to cancer biology. Cancer Res 76:6774\u20136777. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1580","journal-title":"Cancer Res"},{"key":"6569_CR25","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1038\/s41598-018-27521-y","volume":"8","author":"A Nagy","year":"2018","unstructured":"Nagy A, Lanczky A, Menyhart O, Gyorffy B (2018) Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep 8:9227. https:\/\/doi.org\/10.1038\/s41598-018-27521-y","journal-title":"Sci Rep"},{"key":"6569_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13058-015-0550-y","volume":"17","author":"P Jezequel","year":"2015","unstructured":"Jezequel P, Loussouarn D, Guerin-Charbonnel C, Campion L, Vanier A, Gouraud W et al (2015) Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res 17:43. https:\/\/doi.org\/10.1186\/s13058-015-0550-y","journal-title":"Breast Cancer Res"},{"key":"6569_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41419-019-1705-z","volume":"10","author":"XG Zhao","year":"2019","unstructured":"Zhao XG, Hu JY, Tang J, Yi W, Zhang MY, Deng R et al (2019) miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis 10:479. https:\/\/doi.org\/10.1038\/s41419-019-1705-z","journal-title":"Cell Death Dis"},{"key":"6569_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016915","volume":"6","author":"E Enerly","year":"2011","unstructured":"Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG et al (2011) miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS ONE 6:e16915. https:\/\/doi.org\/10.1371\/journal.pone.0016915","journal-title":"PLoS ONE"},{"key":"6569_CR29","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1186\/1471-2164-14-643","volume":"14","author":"E de Rinaldis","year":"2013","unstructured":"de Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz GM, Burford B et al (2013) Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics 14:643. https:\/\/doi.org\/10.1186\/1471-2164-14-643","journal-title":"BMC Genomics"},{"key":"6569_CR30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.05005","author":"V Agarwal","year":"2015","unstructured":"Agarwal V, Bell GW, Nam JW, Bartel DP (2015) Predicting effective microRNA target sites in mammalian mRNAs. Elife. https:\/\/doi.org\/10.7554\/eLife.05005","journal-title":"Elife"},{"key":"6569_CR31","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.1016\/j.biomaterials.2011.07.001","volume":"32","author":"CS Szot","year":"2011","unstructured":"Szot CS, Buchanan CF, Freeman JW, Rylander MN (2011) 3D in vitro bioengineered tumors based on collagen I hydrogels. Biomaterials 32:7905\u20137912. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.07.001","journal-title":"Biomaterials"},{"key":"6569_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/bip.22133","volume":"99","author":"S Motte","year":"2013","unstructured":"Motte S, Kaufman LJ (2013) Strain stiffening in collagen I networks. Biopolymers 99:35\u201346. https:\/\/doi.org\/10.1002\/bip.22133","journal-title":"Biopolymers"},{"key":"6569_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171417","volume":"12","author":"M Anguiano","year":"2017","unstructured":"Anguiano M, Castilla C, Maska M, Ederra C, Pelaez R, Morales X et al (2017) Characterization of three-dimensional cancer cell migration in mixed collagen-Matrigel scaffolds using microfluidics and image analysis. PLoS ONE 12:e0171417. https:\/\/doi.org\/10.1371\/journal.pone.0171417","journal-title":"PLoS ONE"},{"key":"6569_CR34","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1074\/jbc.M008398200","volume":"276","author":"H Kimura","year":"2001","unstructured":"Kimura H, Weisz A, Ogura T, Hitomi Y, Kurashima Y, Hashimoto K et al (2001) Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 276:2292\u20132298. https:\/\/doi.org\/10.1074\/jbc.M008398200","journal-title":"J Biol Chem"},{"key":"6569_CR35","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3389\/fgene.2019.00659","volume":"10","author":"I Rashid","year":"2019","unstructured":"Rashid I, Pathak AK, Kumar R, Srivastava P, Singh M, Murali S et al (2019) Genome-wide comparative analysis of HIF binding sites in cyprinus carpio for in silico identification of functional hypoxia response elements. Front Genet 10:659. https:\/\/doi.org\/10.3389\/fgene.2019.00659","journal-title":"Front Genet"},{"key":"6569_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev-cellbio-100109-104020","volume":"26","author":"P Singh","year":"2010","unstructured":"Singh P, Carraher C, Schwarzbauer JE (2010) Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol 26:397\u2013419. https:\/\/doi.org\/10.1146\/annurev-cellbio-100109-104020","journal-title":"Annu Rev Cell Dev Biol"},{"key":"6569_CR37","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/bjc.2016.312","volume":"115","author":"H Hamidi","year":"2016","unstructured":"Hamidi H, Pietila M, Ivaska J (2016) The complexity of integrins in cancer and new scopes for therapeutic targeting. Br J Cancer 115:1017\u20131023. https:\/\/doi.org\/10.1038\/bjc.2016.312","journal-title":"Br J Cancer"},{"key":"6569_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1158\/1541-7786.MCR-16-0338","volume":"15","author":"JA Ju","year":"2017","unstructured":"Ju JA, Godet I, Ye IC, Byun J, Jayatilaka H, Lee SJ et al (2017) Hypoxia selectively enhances integrin alpha5beta1 receptor expression in breast cancer to promote metastasis. Mol Cancer Res 15:723\u2013734. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0338","journal-title":"Mol Cancer Res"},{"key":"6569_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cancers5010027","volume":"5","author":"F Schaffner","year":"2013","unstructured":"Schaffner F, Ray AM, Dontenwill M (2013) Integrin alpha5beta1, the fibronectin receptor, as a pertinent therapeutic target in solid tumors. Cancers 5:27\u201347. https:\/\/doi.org\/10.3390\/cancers5010027","journal-title":"Cancers"},{"key":"6569_CR40","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1134\/S0006297917090048","volume":"82","author":"GE Morozevich","year":"2017","unstructured":"Morozevich GE, Kozlova NI, Susova OY, Lupatov AY, Berman AE (2017) Hyperexpression of Integrin alpha5beta1 Promotes Resistance of MCF-7 Human Breast Carcinoma Cells to Doxorubicin via ERK Protein Kinase Down-regulation. Biochemistry (Mosc) 82:1017\u20131024. https:\/\/doi.org\/10.1134\/S0006297917090048","journal-title":"Biochemistry (Mosc)"},{"key":"6569_CR41","doi-asserted-by":"publisher","first-page":"24756","DOI":"10.1016\/S0021-9258(17)31456-4","volume":"269","author":"S Aota","year":"1994","unstructured":"Aota S, Nomizu M, Yamada KM (1994) The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem 269:24756\u201324761","journal-title":"J Biol Chem"},{"key":"6569_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/BD-2010-0307","volume":"32","author":"KJ Chavez","year":"2010","unstructured":"Chavez KJ, Garimella SV, Lipkowitz S (2010) Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 32:35\u201348. https:\/\/doi.org\/10.3233\/BD-2010-0307","journal-title":"Breast Dis"},{"key":"6569_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr2889","volume":"13","author":"DL Holliday","year":"2011","unstructured":"Holliday DL, Speirs V (2011) Choosing the right cell line for breast cancer research. Breast Cancer Res 13:215. https:\/\/doi.org\/10.1186\/bcr2889","journal-title":"Breast Cancer Res"},{"key":"6569_CR44","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1007\/s00018-006-6149-9","volume":"63","author":"HA Lucero","year":"2006","unstructured":"Lucero HA, Kagan HM (2006) Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci 63:2304\u20132316. https:\/\/doi.org\/10.1007\/s00018-006-6149-9","journal-title":"Cell Mol Life Sci"},{"key":"6569_CR45","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3389\/fonc.2019.00653","volume":"9","author":"Z Ghaemi","year":"2019","unstructured":"Ghaemi Z, Soltani BM, Mowla SJ (2019) MicroRNA-326 functions as a tumor suppressor in breast cancer by targeting ErbB\/PI3K signaling pathway. Front Oncol 9:653. https:\/\/doi.org\/10.3389\/fonc.2019.00653","journal-title":"Front Oncol"},{"key":"6569_CR46","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3892\/or.2017.5810","volume":"38","author":"S Hu","year":"2017","unstructured":"Hu S, Ran Y, Chen W, Zhang Y, Xu Y (2017) MicroRNA-326 inhibits cell proliferation and invasion, activating apoptosis in hepatocellular carcinoma by directly targeting LIM and SH3 protein 1. Oncol Rep 38:1569\u20131578. https:\/\/doi.org\/10.3892\/or.2017.5810","journal-title":"Oncol Rep"},{"key":"6569_CR47","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/0008-5472.CAN-18-0891","volume":"79","author":"BS Hong","year":"2019","unstructured":"Hong BS, Ryu HS, Kim N, Kim J, Lee E, Moon H et al (2019) Tumor suppressor miRNA-204-5p regulates growth, metastasis, and immune microenvironment remodeling in breast cancer. Cancer Res 79:1520\u20131534. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0891","journal-title":"Cancer Res"},{"key":"6569_CR48","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1158\/2159-8290.CD-15-0893","volume":"6","author":"R Rupaimoole","year":"2016","unstructured":"Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK (2016) miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov 6:235\u2013246. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0893","journal-title":"Cancer Discov"},{"key":"6569_CR49","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.3892\/ol.2017.5852","volume":"13","author":"P Zhang","year":"2017","unstructured":"Zhang P, Kong F, Deng X, Yu Y, Hou C, Liang T et al (2017) MicroRNA-326 suppresses the proliferation, migration and invasion of cervical cancer cells by targeting ELK1. Oncol Lett 13:2949\u20132956. https:\/\/doi.org\/10.3892\/ol.2017.5852","journal-title":"Oncol Lett"},{"key":"6569_CR50","doi-asserted-by":"publisher","first-page":"8341","DOI":"10.18632\/oncotarget.7071","volume":"7","author":"C Sun","year":"2016","unstructured":"Sun C, Huang C, Li S, Yang C, Xi Y, Wang L et al (2016) Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget 7:8341\u20138359. https:\/\/doi.org\/10.18632\/oncotarget.7071","journal-title":"Oncotarget"},{"key":"6569_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12943-016-0557-8","volume":"15","author":"Z Nawaz","year":"2016","unstructured":"Nawaz Z, Patil V, Paul Y, Hegde AS, Arivazhagan A, Santosh V et al (2016) PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA. Mol Cancer 15:74. https:\/\/doi.org\/10.1186\/s12943-016-0557-8","journal-title":"Mol Cancer"},{"key":"6569_CR52","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.bcp.2009.10.017","volume":"79","author":"Z Liang","year":"2010","unstructured":"Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K et al (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 79:817\u2013824. https:\/\/doi.org\/10.1016\/j.bcp.2009.10.017","journal-title":"Biochem Pharmacol"},{"key":"6569_CR53","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","volume":"93","author":"M Hockel","year":"2001","unstructured":"Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266\u2013276. https:\/\/doi.org\/10.1093\/jnci\/93.4.266","journal-title":"J Natl Cancer Inst"},{"key":"6569_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","volume":"14","author":"N Rohwer","year":"2011","unstructured":"Rohwer N, Cramer T (2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14:191\u2013201. https:\/\/doi.org\/10.1016\/j.drup.2011.03.001","journal-title":"Drug Resist Updat"},{"key":"6569_CR55","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrc2540","volume":"8","author":"JA Bertout","year":"2008","unstructured":"Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8:967\u2013975. https:\/\/doi.org\/10.1038\/nrc2540","journal-title":"Nat Rev Cancer"},{"key":"6569_CR56","first-page":"1138","volume":"63","author":"B Krishnamachary","year":"2003","unstructured":"Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G et al (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63:1138\u20131143","journal-title":"Cancer Res"},{"key":"6569_CR57","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00280-006-0224-7","volume":"58","author":"X Song","year":"2006","unstructured":"Song X, Liu X, Chi W, Liu Y, Wei L, Wang X et al (2006) Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 58:776\u2013784. https:\/\/doi.org\/10.1007\/s00280-006-0224-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"6569_CR58","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10549-012-2197-z","volume":"135","author":"SK Botla","year":"2012","unstructured":"Botla SK, Gholami AM, Malekpour M, Moskalev EA, Fallah M, Jandaghi P et al (2012) Diagnostic values of GHSR DNA methylation pattern in breast cancer. Breast Cancer Res Treat 135:705\u2013713. https:\/\/doi.org\/10.1007\/s10549-012-2197-z","journal-title":"Breast Cancer Res Treat"},{"key":"6569_CR59","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1158\/1078-0432.CCR-17-2776","volume":"24","author":"RR Mishra","year":"2018","unstructured":"Mishra RR, Belder N, Ansari SA, Kayhan M, Bal H, Raza U et al (2018) Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer. Clin Cancer Res 24:1987\u20132001. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2776","journal-title":"Clin Cancer Res"},{"key":"6569_CR60","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/s41388-017-0108-9","volume":"37","author":"O Saatci","year":"2018","unstructured":"Saatci O, Borgoni S, Akbulut O, Durmus S, Raza U, Eyupoglu E et al (2018) Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2\/xL in HER2-positive breast cancer. Oncogene 37:2251\u20132269. https:\/\/doi.org\/10.1038\/s41388-017-0108-9","journal-title":"Oncogene"},{"key":"6569_CR61","doi-asserted-by":"publisher","first-page":"49859","DOI":"10.18632\/oncotarget.10489","volume":"7","author":"U Raza","year":"2016","unstructured":"Raza U, Saatci O, Uhlmann S, Ansari SA, Eyupoglu E, Yurdusev E et al (2016) The miR-644a\/CTBP1\/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer. Oncotarget 7:49859\u201349877. https:\/\/doi.org\/10.18632\/oncotarget.10489","journal-title":"Oncotarget"},{"key":"6569_CR62","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","volume":"123","author":"B Gyorffy","year":"2010","unstructured":"Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123:725\u2013731. https:\/\/doi.org\/10.1007\/s10549-009-0674-9","journal-title":"Breast Cancer Res Treat"},{"key":"6569_CR63","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nmeth.3485","volume":"12","author":"H Dweep","year":"2015","unstructured":"Dweep H, Gretz N (2015) miRWalk20: a comprehensive atlas of microRNA-target interactions. Nat Methods 12:697. https:\/\/doi.org\/10.1038\/nmeth.3485","journal-title":"Nat Methods"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06569-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06569-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06569-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T18:06:33Z","timestamp":1652205993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06569-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6569"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06569-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"O.S. is the co-founder and manager of OncoCube Therapeutics LLC and founder and president of LoxiGen, Inc. The other authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}